Vildagliptin one of three new launches for Novartis in Japan
This article was originally published in Scrip
Executive Summary
Novartis has launched three new products in Japan, including the antidiabetic Equa (vildagliptin) and Afinitor (everolimus) for renal cell carcinoma (RCC).